The inhibition of the ABL–IRE1α pathway with selective IRE1a kinase inhibitors or imatinib (tyrosine kinase inhibitor)has been shown to reverse autoimmune diabetes in mice,159 indicating the ABL–IRE1α axis as a potential drug target for treating autoimmune diseases. This evidence concerns the gene ERN1 and autoimmune disease.